Mirvie announced on 3 May it was granted breakthrough device designation from the US Food and Drug Administration for a blood test to indicate a woman’s risk of developing preeclampsia, a complication of pregnancy, before symptoms occur.
The South San Francisco-based company developed the Mirvie RNA platform which analyzes tens of thousands of RNA messages from the baby, the placenta and the mother, using machine learning, to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?